| scholarly article | Q13442814 |
| P50 | author | Szu-Chia Chen | Q60959245 |
| Tsung-Hsien Lin | Q74664543 | ||
| Ho-Ming Su | Q79162089 | ||
| Po-Chao Hsu | Q88503662 | ||
| P2093 | author name string | Chee-Siong Lee | |
| Wen-Ter Lai | |||
| Hsueh-Wei Yen | |||
| Sheng-Hsiung Sheu | |||
| Wen-Chol Voon | |||
| Chun-Yuan Chu | |||
| Wen-Hsien Lee | |||
| Hung-Hao Lee | |||
| Meng-Kuang Lee | |||
| P2860 | cites work | The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events | Q33693990 |
| Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling | Q33819399 | ||
| Left ventricular hypertrophy: pathogenesis, detection, and prognosis | Q33977917 | ||
| A Comparison between Brachial and Echocardiographic Systolic Time Intervals | Q34586348 | ||
| Targeting the CaMKII/ERK Interaction in the Heart Prevents Cardiac Hypertrophy | Q35674329 | ||
| CaMK4 Gene Deletion Induces Hypertension | Q36366241 | ||
| Mechanisms of cardiac hypertrophy. | Q36770771 | ||
| Cardiorenal syndrome: new perspectives | Q37765094 | ||
| G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms | Q38093493 | ||
| β-adrenoceptors as molecular targets in the treatment of hypertension | Q38200770 | ||
| Myocardial remodeling in hypertension | Q38209968 | ||
| Cardiorenal syndrome in chronic kidney disease | Q38337763 | ||
| Integrating GRK2 and NFkappaB in the Pathophysiology of Cardiac Hypertrophy | Q38848001 | ||
| Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-kappaB-dependent hypertrophic gene expression. | Q39675542 | ||
| A new systolic parameter defined as the ratio of brachial pre-ejection period to brachial ejection time predicts overall and cardiovascular mortality in hemodialysis patients. | Q43142479 | ||
| Left ventricular hypertrophy and progression of chronic kidney disease | Q44568847 | ||
| Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. | Q46099970 | ||
| Left ventricular hypertrophy in nondiabetic predialysis CKD. | Q46660190 | ||
| The Pl(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. | Q48284904 | ||
| Cardiovascular disease and subsequent kidney disease | Q50155784 | ||
| Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure | Q50957091 | ||
| Does the ID-MS traceable MDRD equation work and is it suitable for use with compensated Jaffe and enzymatic creatinine assays? | Q51941042 | ||
| Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings | Q52429603 | ||
| Myocardial performance index derived from brachial-ankle pulse wave velocity: a novel and feasible parameter in evaluation of cardiac performance | Q54642251 | ||
| Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio | Q57217547 | ||
| Left Ventricular Mass | Q57243092 | ||
| Electrocardiographic abnormalities and uremic cardiomyopathy | Q57750263 | ||
| Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives | Q61456615 | ||
| A comparison of systolic time intervals derived from the central aortic pressure and from the external carotid pulse tracing | Q66908830 | ||
| Left ventricular mass and systolic performance in chronic systemic hypertension | Q69987967 | ||
| Chronic kidney disease in patients with chronic heart failure--impact on intracardiac conduction, diastolic function and prognosis | Q79268221 | ||
| Time intervals and global cardiac function. Use and limitations | Q81121058 | ||
| Impact of systolic time intervals on the relationship between arterial stiffness and left ventricular hypertrophy | Q84223704 | ||
| A systolic parameter defined as the ratio of brachial pre-ejection period to brachial ejection time predicts cardiovascular events in patients with chronic kidney disease | Q84799701 | ||
| New insights into the relationship of left ventricular geometry and left ventricular mass with cardiac function: A population study of hypertensive subjects | Q84940431 | ||
| Significant correlation between ratio of brachial pre-ejection period to ejection time and left ventricular ejection fraction and mass index in patients with chronic kidney disease | Q85175919 | ||
| Left Ventricular Ejection Time Derived From the Common Carotid Artery Doppler Waveform: Association With Left Ventricular Ejection Fraction and Prediction of Heart Failure | Q85472707 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systole | Q496359 |
| P304 | page(s) | e2917 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Medicine (Barcelona) / Programa de Educación Médica Continuada (EMC) en medicina Asistencial | Q29044007 |
| P1476 | title | Estimated Glomerular Filtration Rate and Systolic Time Intervals in Risk Stratification for Increased Left Ventricular Mass Index and Left Ventricular Hypertrophy | |
| P478 | volume | 95 |
| Q36045060 | Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis |
| Q33868118 | Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease |
Search more.